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RESUME 
Les parasitoses constituent une importante cause de morbi-mortalité dans le monde, et plus 
particulièrement dans les pays à faibles ressources où la prévalence de telles infections est très 
élevée. Leurs conséquences chez la femme enceinte constituent un problème de santé 
publique. Savoir maîtriser les infections, souvent associées entre elles, sans risquer de nuire à 
la grossesse et à l’intégrité du fœtus, représente donc un réel défi pour le thérapeute. Pourtant, 
en régions tempérées comme tropicales, les vraies révolutions antiparasitaires sont rares et 
l’arsenal thérapeutique demeure limité. Les informations scientifiques sont lacunaires car les 
études cliniques incluant des femmes enceintes sont peu nombreuses. Le prescripteur doit 
donc savoir jongler astucieusement avec les molécules actives à disposition, et connaître les 
effets embryo- et fœtotoxiques de chacune d’elles. Les pratiques médicales doivent être 
adaptées au terme de la grossesse et à l’urgence à traiter la mère. 
 
 
  
Abstract 
Parasitoses are a major cause of morbidity and mortality worldwide, especially in resource-
poor countries where the prevalence of such infections is very high. Their consequences for 
pregnant women are a public health issue. It is very challenging to successfully control 
parasitic infections with the dedicated drugs, while protecting the fetus from the harmful 
effects of these medications. However, in both temperate and tropical regions, true 
antiparasitic innovations are rare, and the therapeutic armamentarium remains limited. 
Scientific data is incomplete as only a few clinical studies have included pregnant women so 
far. Therefore, physicians have to learn how to thoroughly handle the antiparasitic molecules 
available. They also need to know the embryo- and fetotoxic effects of each of them. Medical 
practices must be adapted to the trimester of pregnancy. 
 
INTRODUCTION 
A large part of the world’s population is exposed to parasitic infections and several of them 
may even occur simultaneously. Consequences may be severe for pregnant women but also 
for the embryo or fetus (1,2). However, dedicated agents are scarce compared with the 
antibiotics available for pregnant women, and no specific vaccine is available (3). Research 
and development are limited in this field compared with antiviral drugs. Choosing the right 
antiparasitic chemotherapy is therefore extremely difficult because, besides cost and 
availability issues, the chosen chemotherapy must offer the perfect balance between control 
of the infection and of the drug-related embryotoxic or fetotoxic effects (4). Yet, literature 
data on the use of antiparasitic drugs in pregnant women is very limited. It is often ethically 
difficult for investigators and pharmaceutical companies to conduct large-scale clinical trials 
in this population. 
Each parasitic infection used to be treated with specific drugs − most often toxic −, but the 
few recent agents tend to have a wider spectrum of activity and are overall better tolerated. 
We aimed to update knowledge on the use of antiparasitic drugs in pregnant women (Table 
1). 
 
1. ANTIMALARIAL DRUGS 
Malaria is a parasitic infection which mainly occurs in intertropical regions. It is caused by 
erythrocytic protozoa of the Plasmodium genus, and the virus is transmitted by Anopheles 
mosquito bites. P. falciparum and to a lesser extent P. vivax are the only species with a real 
impact on pregnancy outcome (5). Malaria contracted during pregnancy is associated with a 
two- or three-fold increased risk of maternal anemia and severe presentations such as 
cerebral malaria (6). Consequences for the embryo and fetus are due to placental parasitism. 
The placenta loses its integrity and no longer ensures normal transplacental exchange 
(nutrients and oxygen). This results in a low birth weight, especially in newborns with 
primigravida or secundigravida mother (7). Malaria is therefore responsible for 14% of low 
birth weight cases worldwide. The outcome is often unfavorable as an estimated 200,000 
infants die every year due to the consequences of maternal malaria contracted during 
pregnancy (5). 
 
a. Aminoquinolines 
i. 4-aminoquinolines 
This class includes chloroquine (Nivaquine®); an old and well-absorbed product after oral 
administration. Its schizonticidal action relies on its alkaline properties which favor its 
accumulation in the endocytic vacuole of the intraerythrocytic parasite. Inside the vacuole, 
chloroquine blocks the elimination of toxic heme residuals, especially ferriprotoporphyrin IX. 
The latter can thus no longer be metabolized into hemozoin, i.e. the soluble pigment (8). 
Blood levels of chloroquine in the umbilical cord are equivalent to those of the mother. High 
doses of chloroquine are responsible for teratogenic effects in animal models. However, its 
use in humans does not induce spontaneous abortion nor does it induce the in utero death 
of the fetus or malformations (9). The structure of amodiaquine (Flavoquine®) is close to that 
of chloroquine. It does not induce severe toxicity for the embryo or fetus, but it is still poorly 
used because of its hepatic toxicity and myelotoxicity (10). Pyronaridine is quite similar to 
amodiaquine. It is used in combination with an artemisinin derivative (Pyramax®), but it has 
been shown toxic for the embryo in rats (11). 
Chloroquine may be administered to pregnant women, irrespective of the pregnancy 
trimester. As a curative treatment, it can be administered without any restriction at a dose 
of 10 mg/kg on the first day, 10 mg/kg on the second day, and 5 mg/kg on the third day to 
treat uncomplicated malaria episodes caused by non-P. falciparum Plasmodium species. 
 
ii. 8-aminoquinolines 
Primaquine is an 8-aminoquinoline prescribed for the prevention of P. vivax and P. ovale 
malaria relapses. Primaquine is able to eradicate quiescent parasitic forms in the liver. It is 
readily absorbed from the gastrointestinal tract. It is contraindicated in pregnant women as 
it is responsible for severe hemolytic anemia. 
 
b. Alkanolamines 
i. Natural alkanolamines  
Quinine (Quinimax®, Surquina®, Quinine Lafran®) is an alkaloid extracted from the bark of 
cinchona trees, with moderately rapid schizonticidal properties. Quinine is rapidly absorbed 
from the oral route, although with low transplacental passage. Ocular and hearing 
impairments have been reported in children whose mother had received high doses of 
quinine. Supratherapeutic doses of quinine are misused because of its oxytocic properties, 
which lead to using the drug as an abortion drug especially in women presenting with 
contractions. 
Quinine remains the first-line treatment of uncomplicated P. falciparum episodes during the 
first trimester of pregnancy (12). Its daily dosage is 25 mg/kg divided into three intakes, for 
seven days. 
 
ii. Synthetic alkanolamines  
Mefloquine (Lariam®) is readily absorbed from the oral route. Experimental studies 
performed in pregnant rats revealed that very high doses of mefloquine had a fetotoxic 
effect. In humans, mefloquine has long been suspected of increasing the risk of spontaneous 
abortions and in utero death of the fetus, even at low doses (13). However, a study 
monitoring the pregnancy of military women who were first unaware of their pregnancy and 
were inadvertently exposed to mefloquine, did not reveal any significant increase in fetal 
malformations (14). A larger scale retrospective study, based on the analysis of pregnancies 
from 1986 to 2010, did not report an increased incidence of malformations nor an increased 
rate of spontaneous abortions (15).  
Mefloquine can therefore be used alone as a prophylactic treatment, irrespective of the 
number of weeks of amenorrhea (12). In such cases, the dosage is 250 mg every week (taken 
with food). Treatment must be continued for three weeks following return home. The 
curative treatment with mefloquine is prescribed to patients presenting with uncomplicated 
P. falciparum malaria only, when quinine is contraindicated (12). Its dosage is 25 mg/kg over 
one day only, divided into two intakes of 15 mg/kg followed by 10 mg/kg 12 hours later or 
into three intakes of 8 mg/kg every 6-8 hours. 
Lumefantrine is an alkanolamine derivative associated with arthemeter, which is derived 
from artemisinin (Riamet®). Lumefantrine is indicated, during the second and third 
trimesters of pregnancy, in the curative treatment of uncomplicated malaria episodes. Its 
dosage is 80 mg twice daily for three consecutive days, combined with 480 mg of arthemeter 
twice daily. Halofantrine (Halfan®), another synthetic alkanolamine, is no longer 
commercialized in France since 2016. It was contraindicated in pregnant women because of 
its embryotoxicity.  
 
c. Inhibitors of folic acid synthesis 
Inhibitors of folic acid synthesis include antifolic drugs of the sulfonamide class such as 
sulfadoxine, and antifolates such as proguanil and pyrimethamine. Inhibitors of folic acid 
inhibit the dihydropteroate synthase while antifolates block the dihydrofolate reductase, 
which are both essential for the nucleic acid synthesis of the parasite. 
Sulfonamides have a good transplacental diffusion. For instance, plasma levels of sulfadoxine 
in fetuses are comparable to those observed in mothers. A teratogenic effect has been 
observed in animals, although never confirmed in humans. However, sulfonamides have the 
capacity to move bilirubin binding sites which can induce nuclear jaundice in fetuses, 
especially with products with a long half-life such as sulfadoxine. Administering sulfonamides 
at the end of pregnancy in case of congenital glucose-6-phosphate dehydrogenase deficiency 
is associated with a risk of neonatal hemolysis. 
Pyrimethamine is associated with a very good transplacental passage as its serum 
concentration in fetuses is 50% to 100% that of the mother (16). Pyrimethamine 
administration during the first trimester of pregnancy has been associated with teratogenic 
effects in animals. Proguanil can be safely used, irrespective of the pregnancy term.  
To prevent congenital malaria in endemic areas, it is recommended to initiate an 
intermittent preventive treatment (IPT) based on the combination of sulfadoxine and 
pyrimethamine (Fansidar®) administered three times one month apart, from Week 16 of 
amenorrhea (17). Folic acid administration during pregnancy at the dosage of 0.4 mg daily 
(18) or folinic acid administration at the dosage of 3-5 mg three times a week (19), remains 
beneficial to prevent congenital disorders as well as cytopenia in mothers.  
 
d. Cyclins 
The gastrointestinal absorption of cyclins is incomplete, but they do cross the feto-placental 
barrier. Whether for a prophylactic or a curative use, cyclins such as doxycycline 
(Vibramycine®) are not recommended in pregnant women beyond the first trimester. They 
may induce a coloration of the unborn child’s deciduous teeth when administered for at 
least 15 days. When cyclins must imperatively be administered, the prophylactic dosage is 
100 mg of doxycycline daily for the whole duration of the stay in a malaria-endemic area. 
Daily intakes must be continued for one month following return in the home country. 
 e. Artemisinin derivatives  
Artemisinin derivatives are sesquiterpene lactones isolated from a plant called Artemisia 
annua. They are very fast-acting schizonticidal antimalarial drugs. They act at the parasite’s 
food vacuole level by binding to the heme and inducing an oxidative stress which triggers the 
release of free radicals toxic for the parasite (20). 
Artemisinin derivatives are embryotoxic for the heart and are responsible for skeletal 
malformations in various animal species. Studies of pregnant rats demonstrated harmful 
effects on the yolk bag which induced hematopoietic disorders in embryos. Exposure to 
higher doses of artemisinin derivatives decreased the angiogenesis which could lead to the 
in utero death of the fetus by hypoxia or to spontaneous abortion (21). A study performed 
with monkeys is currently ongoing to understand the mechanisms of this toxicity (22). 
However, the study of a very limited number of pregnant women accidentally exposed to 
artemisinin-based treatments during their first trimester did not show any major teratogenic 
effect (23). More exhaustive data is available for the second and third trimesters with 
bioclinical data from more than 4,000 pregnant women. These findings indicated that the 
use of artemisinin derivatives did not increase the rate of adverse events, both for the 
mother and fetus (23). 
Artemisinin derivatives are indicated in the treatment of uncomplicated malaria when orally 
administered as part of a combination with piperaquine (Eurartesim®) or lumefantrine 
(Riamet®), but also in the treatment of complicated P. falciparum malaria (as injections) in 
pregnant women at the second and third trimesters of pregnancy. Artemisinin derivatives 
may also be urgently administered during the first trimester of pregnancy. The reference 
treatment for severe malaria is parenteral artesunate in monotherapy (Malacef®, temporary 
marketing authorization in France) at the daily dosage of 2.4 mg/kg for seven days, except 
the first day as the dosage needs to be multiplied by three on that day (12). 
 
f. Other antimalarial drugs 
Atovaquone is an inhibitor of the pyrimidine biosynthesis. It is used as part of a two-drug 
combination with an antifolate: proguanil (Malarone®). Atovaquone targets the parasite’s 
mitochondrion where it blocks the electron transfer chain at a key enzyme level 
(dihydroorotate reductase), as well as the cytochrome b1 complex replacing ubiquinone. 
This process results in the inhibition of the mitochondrial respiratory chain.  
Atovaquone has sometimes been associated with embryotoxicity in animals, but the 
mechanism of action remains unknown and disputed. Clinical data in pregnant women is 
very reassuring. The atovaquone-proguanil combination may be suggested as a curative 
treatment at the daily dosage of 1,000 mg of atovaquone and 400 mg of proguanil for three 
consecutive days. Tablets must be taken with high-fat food. Its prophylactic use is also 
possible in pregnant women, when the travel cannot be delayed and when the visited area is 
highly endemic for malaria (12). The daily dosage is in that case one tablet containing 
250 mg of atovaquone and 100 mg of proguanil. Treatment must be continued daily up to 
one week following return home. 
 
2. ANTI-TOXOPLASMA DRUGS  
Toxoplasmosis is a worldwide parasitic infection caused by the protozoa Toxoplasma gondii. 
It is orally transmitted from soiled water or plants or from undercooked meat. Clinical 
presentations in pregnant women are similar to those observed in any other adult (24). The 
mother-to-fetus transmission risk is directly related to the placental characteristics: the 
more permeable the placenta during pregnancy, the more likely the transmission of parasitic 
vegetative forms. Conversely, the congenital infection severity is higher when occurring at 
the early stage of pregnancy (25). The prognosis is often very poor, with spontaneous 
abortion, in utero fetal death, or severe malformations characterized by hydrocephalus, 
intracranial calcifications, retinochoroiditis, and various organogenesis disorders (24).  
 
a. Macrolides 
Spiramycin (Rovamycine®) is a macrolide with a parasitostatic action against vegetative 
forms of Toxoplasma, probably due to its metabolites produced in vivo. Spiramycin does not 
cross the feto-placental barrier and its safety has already been proven. 
Although its efficacy is disputed (26), spiramycin is indicated in the antenatal prevention of 
congenital toxoplasmosis in women contaminated during pregnancy. The recommended 
dosing regimen is 3 million of units three times a day until delivery or until the congenital 
infection is confirmed. 
 
b. Inhibitors of folic acid synthesis 
Antifolic agents and antifolates are prescribed to pregnant women with confirmed 
congenital transmission (27). Even in the absence of well-conducted head-to-head clinical 
trial (28,29), the pyrimethamine-sulfadiazine combination is still the most widely used to 
treat in utero congenital toxoplasmosis (30). The daily dosing regimen until delivery is 
1 mg/kg for pyrimethamine and 100-150 mg/kg for sulfadiazine (31). 
 
3. ANTILEISHMANIAL DRUGS 
Visceral leishmaniasis is a severe parasitic infection observed in warm areas and associated 
with poor prognosis. The causative agent − Leishmania spp. − is transmitted to humans 
through the bites of sandflies. Clinical presentations in pregnant women are similar to those 
of any other infected individual (32). The risk of congenital transmission is low. Newborns 
usually develop signs of infection within the first 18 months of life (33).  
 
a. Antimonial drugs 
The class of pentavalent antimonials includes two drugs with similar efficacy: meglumine 
antimoniate (Glucantime®) and sodium stibogluconate (Pentostam®). Antimonial drugs 
acquire their in vivo activity following reduction with acid pH and high temperature. They are 
thus more active against intracellular presentations of leishmaniasis (32) as they can induce 
the reduced synthesis of ATP. 
Antimonial drugs are able to cross the feto-placental barrier. A study conducted in pregnant 
rats did not report any adverse event in female rats but did report a higher lethality among 
embryos. A lower lethality was observed with a single administration of a high dose rather 
than repeated administrations − even at low doses. With the single administration, the 
antimony is preserved in only one compartment with a rapid elimination phase while 
repeated administrations are associated with antimony conservation in two compartments 
including one with a slow elimination phase which is responsible for toxic accumulation (34). 
The authors of an animal study using dosages only 15 to 30 times higher than those used in 
humans, reported an increased rate of bone malformations and a lower fetal weight. 
Antimony derivatives also penetrate into the neural tissues of fetuses and may induce 
severe learning disability (35). The use of antimonial drugs at the early stage of pregnancy 
may highly impair the embryo development especially as treatment for visceral leishmaniasis 
usually requires daily administrations of high doses (70 mg/kg) for a month. Meglumine 
antimoniate and sodium stibogluconate may be prescribed from the end of the third month 
of pregnancy, but less toxic alternatives must be considered to treat visceral leishmaniasis. 
 
b. Pentamidine 
Pentamidine isethionate (Pentacarinat®) is a stable diamidine with a mechanism of action 
still not entirely understood. It is believed to inhibit the parasitic DNA synthesis by blocking 
the thymidine-synthetase following binding to the transfer RNA (36). 
Pentamidine is able to cross the feto-placental barrier of female rats. At the end of 
gestation, it reaches cerebral concentrations in fetuses close to those observed in maternal 
serum. It is also observed at significant levels in the liver and renal tissues of baby rats. The 
placental transfer of pentamidine has never been studied in pregnant women (37). First-
trimester miscarriages have been reported with pentamidine aerosol administration in other 
indications. 
Usually prescribed as a short-term treatment at the dosage of 3-4 mg/kg every two or three 
days for two weeks, pentamidine is not recommended as the first-line treatment of 
leishmaniasis in pregnant women, unless its use is essential. Such scenario is not very likely 
as alternatives are available with amphotericin B. 
 
a. Amphotericin B 
Amphotericin B is a lipophilic polyunsaturated organic compound of the polyenes family. It 
binds to the precursors of ergosterol of the Leishmania cell membrane, leading to an 
increased permeability through which ions leak out of the cell, and to the membrane lysis 
(38). 
The molecule is able to cross the feto-placental barrier, but the fetal blood level does not 
exceed a third of the maternal blood level (32). Standard amphotericin B deoxycholate 
(Fungizone®) has been administered to animals at experimental doses up to 10 times higher 
than those used in humans. No teratogenicity has been observed, including during the first 
trimester of gestation. No lethality for the embryo or toxicity for the fetus has so far been 
observed in clinical studies of pregnant women (32). A few cases of moderate and transitory 
renal failure leading to a decreased amount of amniotic fluid have been reported with the 
administration of amphotericin B deoxycholate at the end of pregnancy. The authors of a 
head-to-head study did not report any significant increase in spontaneous abortions or 
malformations with the administration of lipid formulations of amphotericin B (39). 
Liposomal amphotericin B (AmBisome®) is currently the first-line treatment of visceral 
leishmaniasis in pregnant women. It can be used at the dosage of 3 mg/kg per day for five 
consecutive days, followed by a sixth injection on day 10. 
 
4. ANTI-HUMAN AFRICAN TRYPANOSOMIASIS (HAT) DRUGS 
Trypanosomiasis is a severe parasitic infection due to flagellate protozoa of the 
Trypanosoma genus. They are transmitted by arthropods. Human African trypanosomiasis 
(HAT), also known as sleeping sickness, is caused by Tr. brucei gambiense or Tr. brucei 
rhodesiense. It is responsible for subacute neurological and psychiatric signs and may also 
lead to mother-to-fetus transmission (40) (41). The impact on pregnancy is an increase in 
spontaneous abortions, neonatal mortality, or premature births (42), but also an increased 
incidence of hydramnios or pre-eclampsia cases. Congenital presentations are responsible 
for severe and irreversible neurological disorders in newborns as well as for hydrocephalus 
(43). The American presentation of trypanosomiasis, known as Chagas disease, is caused by 
the Tr. cruzi species (44). Mothers present with the same symptoms − although more severe 
− as the ones observed in any other adult: cardiac diseases, megacolon, or achalasia. 
Congenital infections in newborns may present as a clinical manifestation with fever, 
jaundice, edema, hemorrhages, hepatomegaly, and possible cardiac and neurological 
disorders. 
 
a. Suramin 
Suramin sodium (Moranyl®) is believed to have a trypanocidal action against African 
Trypanosoma via the morphological impairment of the intracellular components of the 
membrane. It impacts the absorption and intralysosomal digestion of proteins. 
Congenital malformations have been observed in pregnant rats (45). Suramin sodium is 
currently indicated in the treatment of HAT caused by Tr. b. rhodiense during the first stage 
of the infection, known as the hemolymphatic phase. Although theoretically contraindicated 
in pregnant women, it may be administered at the dosage of 20 mg/kg via slow intravenous 
injections every five to seven days when mothers incur high risks at the neurological phase 
of the infection. 
 
b. Pentamidine 
Pentamidine isethionate may be used to treat the mother and to reduce the vertical 
transmission risk during Tr. b. gambiense infection at the hemolymphatic phase. However, 
its use is only recommended after the first trimester because of the abortive action of the 
drug (43). Pregnant women presenting with neurological presentations of Tr. b. gambiense 
infection may, however, receive pentamidine without any restriction and irrespective of the 
pregnancy stage. The expected benefit overcomes the risk incurred by the fetus. The 
recommended dosing regimen is 7 to 10 intramuscular injections of 4 mg/kg every day or 
every other day (46). 
 
c. Eflornithine 
Alpha-difluoromethylornithine, or eflornithine (Ornidyl®), has a trypanostatic action (47). 
Alpha-difluoromethylornithine has a slow mechanism of action based on its structural 
analogy with ornithine, leading to the inhibition of ornithine decarboxylase and of the cell 
division cycle. Eflornithine is more active against Tr. b. gambiense than Tr. b. rhodesiense, 
probably because the cycle of ornithine in Tr. b. rhodesiense is too rapid (48). 
Eflornithine was found toxic for the embryo and the fetus in pregnant animal models. It was 
associated with growth retardation and central nervous system impairment in fetuses. The 
topical use of eflornithine in pregnant women presenting with facial hirsutism was 
associated with spontaneous abortions, but the study lacked power to conclude on a real 
effect (49).  
The use of eflornithine alone is possible in pregnant women, especially when the mother’s 
general status is moderately or highly impaired (50). The recommended dosing regimen is 
one intravenous injection of 100 mg/kg every six hours for 14 days. At the end of the 
treatment cycle, the cure rate is approximately 97% (51). 
 
d. Melarsoprol  
Melarsoprol (Arsobal®) is a highly toxic organic arsenic compound. It is currently only 
indicated at the neurological phase of Tr. b. rhodesiense HAT and at the advanced stages of 
Tr. b. gambiense presentations in case of relapse following an initial treatment with 
eflornithine. Melarsoprol cannot be used in pregnant women. Treatment must be delayed 
until the mother has given birth, or it must be based on another HAT drug such as 
pentamidine. 
 
e. Other American trypanosomiasis drugs 
Benznidazole (Radanil®), a nitroimidazole derivative, and nifurtimox (Lampit®), a nitrofuran 
derivative, are two trypanocidal drugs with a temporary marketing authorization in the 
treatment of Chagas disease.  
They are readily absorbed from the digestive route. They are not officially contraindicated in 
pregnant women, except at the first trimester. After the first trimester, they can only be 
used when absolutely essential because of the medullary and neurological toxicity of 
benznidazole and because of severe digestive, neuropsychiatric, and neurological disorders 
associated with nifurtimox.  
 
5. ANTHELMINTICS 
Helminthiases are parasitic infections caused by various species of worms. Carriage may 
have a major indirect impact on pregnancy. For instance, hookworms are duodenal 
roundworms feeding from the abrasion of the digestive mucous membrane. They are 
associated with blood loss resulting in iron deficiency anemia. Besides anemia, trichuriasis is 
responsible for dysenteric symptoms. Helminthiases are associated with deficiencies, which 
in turn increase the risk of premature birth or low birth weight (52). 
 
a. Benzimidazole derivatives 
i. Nematicides 
The benzimidazole family includes albendazole (Zentel®), mebendazole (Vermox®) and its 
fluorinated derivative, i.e. flubendazole (Fluvermal®). Benzimidazoles act on the cytoskeleton 
of helminths by inhibiting the polymerization of tubulins and their incorporation into the 
microtubules (53). This phenomenon induces a decreased release of neuromuscular 
mediators and interferes with the absorption of glucose. The parasite is thus paralyzed. It 
can then be passively eliminated in stools. Benzimidazoles are mainly nematicide − especially 
against hookworms, roundworms, whipworms, and oxyuris − and to a lesser extent 
trematocidal and cestocidal.  
Benzimidazoles have low bioavailability or even non-existent bioavailability for flubendazole. 
Preclinical studies of animal models showed that these derivatives may have a teratogenic 
effect. For instance, when administered at the pre-implantation phase, albendazole was 
associated with a decreased bovine embryonic cell division capacity (54). At the 
organogenesis phase, its prolonged use in pregnant rats was associated with skeleton 
impairment at concentrations close to those used in humans. Mebendazole and 
flubendazole were always associated with teratogenic effects and embryonic lethality at high 
doses, respectively (55,56). At intermediate doses, flubendazole was responsible for 
malformations mainly impairing the eyes and neurological development. Published data on 
pregnant women exposed to albendazole during the first trimester is scarce. However, no 
safety signal has been reported so far. Data on the use of albendazole during the second and 
third trimesters of pregnancy is reassuring. At therapeutic doses, a randomized controlled 
study did not report any teratogenic effect of mebendazole in pregnant women at 10 weeks 
of amenorrhea (57). Flubendazole has been extensively used and no safety signal has so far 
been reported.  
Flubendazole may be used in pregnant women, irrespective of the stage and even at the first 
trimester. Albendazole and mebendazole may be prescribed without any restriction during 
the last two trimesters of pregnancy, but they are usually administered as a second-line 
treatment during the first trimester. The recommended dosing regimen for flubendazole is 
200 mg daily for three days. For the particular cases of oxyuriasis, the recommended 
regimen is a single dose of 100 mg to be repeated two or three weeks later. The 
recommended regimen for albendazole is a single dose of 400 mg, except for 
trichocephalosis which requires two administrations of the initial dose and for some larval 
cestodiases such as echinococcosis or cysticercosis requiring 15 mg/kg per day for 15-30 
days. Mebendazole has a temporary marketing authorization. It must preferably be taken 
without food as a single dose of 500 mg for ascaridiosis, and 100 mg twice daily for three 
days for ankylostomosis and trichocephalosis. Oxyuriasis may be treated with 100 mg of 
mebendazole, but the administration must be repeated two or three weeks later. For the 
particular cases of larval cestodiasis, the dosing regimen of mebendazole is 4.5 g per day 
divided into three daily intakes for six months.  
 
ii. Trematocides 
Triclabendazole (Egaten®) is indicated in trematode infections such as Fasciola hepatica or F. 
gigantica fascioliasis at the single dose of 10 mg/kg following food ingestion. No teratogenic 
effect has been observed in preclinical studies of pregnant rats and rabbits. As a precaution, 
triclabendazole must only be used in pregnant women when absolutely necessary and 
preferably after the first trimester. 
 
b. Pyrantel  
Pyrantel pamoate (Combantrin®) is mainly active against nematodes. Just like an 
acetylcholine agonist, although 100 times more efficient, pyrantel is able to activate the 
parasite’s nicotinic receptors in the long-term. This leads to a neuromuscular inhibition and 
induces spastic paralysis. Worms are then eliminated through intestinal peristalsis (58).  
In animals pyrantel is poorly absorbed and is not teratogenic. Very few clinical studies have 
been performed in humans to assess its potential toxic effects during pregnancy. It has, 
however, been used for many years in the mass treatment of hundreds of millions of people, 
including pregnant women. One may thus assume that there is no major risk associated with 
its use. 
Pyrantel is indicated in the treatment of oxyuriasis, ascariasis, and hookworm infections. The 
usual dosing regimen is 10-12 mg/kg, that should be repeated two or three weeks later in 
case of oxyuriasis. Hookworm infections must be treated with the daily dosage of 20 mg/kg 
for two or three days. 
 
c. Avermectins 
Avermectin derivatives are generated as fermentation products by Streptomyces avermitilis. 
They have potent anthelmintic and acaricidal-insecticidal properties mainly against 
nematodes. They bind to glutamate-gated chloride channels in invertebrate nerve and 
muscle cells. Membrane permeability to chloride ions is thus increased, leading to the 
definitive hyperpolarization of the cell. The worm is thus paralyzed and dies. 
The repeated use of avermectins at high doses in pregnant animals was associated with fetal 
toxicity on the central nervous system and with cleft palate occurrences. However, in 
humans, the accidental exposure to avermectins of more than 200 pregnant women during 
the first trimester of pregnancy was not associated with increased embryotoxic effects or 
malformations (59).  
Ivermectin (Stromectol®) is the most frequently used drug among the avermectin family. It is 
indicated in the treatment of nematosis, but its action is quite varied, and its use is 
particularly interesting in endemic areas. The massive prescriptions of ivermectin during 
mass campaigns to women with unknown pregnancy were not associated with any specific 
adverse event. However, the WHO does not recommend its use in pregnant women as a 
systematic chemoprevention of helminthiases as clinical studies evaluating its safety are not 
robust enough (60). However, ivermectin may be used as a curative treatment if its 
prescription is absolutely required, irrespective of the pregnancy term. The recommended 
dosing regimen is 200 µg/kg as a single dose to be taken without food. 
 
d. Praziquantel 
Praziquantel (Biltricide®) is a compound of the pyrazinoisoquinolines family active against 
various genuses of trematodes, and mainly against all species of Schistosoma (61). The drug 
induces the contraction of the parasites, resulting in paralysis in the contracted state. 
Praziquantel increases the permeability of the membranes of schistosome cells towards 
calcium ions, leading to hyperpolarization and paralyzing contraction of the helminth which 
is then dislodged from the host’s tissues. The increased permeability towards calcium 
induced by praziquantel also leads to the vacuolation of the worm’s membrane. It kills both 
adult and larval stage worms.  
Praziquantel is readily absorbed from the oral route. No mutagenic, toxic, or teratogenic 
effect has been observed in animal models. A randomized double blind clinical trial of 
pregnant women between 12 and 16 weeks of amenorrhea did not report any increased risk 
of in utero fetal death or spontaneous abortion, nor any congenital malformation or low 
birth weight (62). A study performed in Uganda demonstrated the safety of praziquantel 
during the second trimester and at the beginning of the third trimester of pregnancy (63). 
Besides for treating schistosomiasis, praziquantel is indicated in the management of tropical 
fascioliasis with three doses of 25 mg/kg over 24 hours. Praziquantel is also used as the first-
line one-dose treatment of intestinal teniasis. This use is, however, off-label and must be 
avoided during the first trimester of pregnancy: the recommended dosing regimen is 
10 mg/kg. It must be taken with fluid and food or just after food ingestion. The 
recommended dosing regimen is 20 mg/kg in case of bothriocephalosis or teniasis caused by 
Hymenolepis nana. Cysticercosis usually requires a long-term treatment with high doses of 
praziquantel: 45 to 60 mg/kg per day divided into three fractionated intakes for 14 days. This 
dosing regimen is a priori contraindicated in pregnant women except for severe clinical 
presentations.  
 
e. Niclosamide 
Niclosamide (Trédémine®) is only active against adult tenia and is inactive against larval stage 
worms. It blocks the citric acid cycle of the parasite, thus impairing the worm metabolism 
and making it more vulnerable to proteolytic enzymes of the host. Tenia then dies inside the 
host’s intestine (58). 
Niclosamide is poorly absorbed from the oral route. Preclinical studies demonstrated that 
niclosamide was not associated with mutagenic, teratogenic, or embryotoxic effects. Such 
effects have also not been observed with therapeutic doses in humans.  
Niclosamide is currently used as the second-line treatment of teniasis, following praziquantel 
(64). The treatment is administered over one day: fasting pregnant women must chew very 
slowly 1 gram of niclosamide and must renew the intake one hour later. Patients cannot 
drink nor eat in the following three hours of the last intake. In particular cases of H. nana 
infection, the daily dose is four tablets on the first day to be taken with food and with acid 
fruit juice, followed by two tablets at the end of meals for a week.  
 
6. ANTIAMOEBIC DRUGS AND OTHER DIGESTIVE ANTIPARASITIC DRUGS  
Consequences of a parasitic infection caused by a digestive protozoan in mothers are overall 
less severe than those of helminthiasis. 
 
a. Imidazoles 
Metronidazole (Flagyl®) is the most frequently used drug among the 5-nitroimidazole 
derivatives. Metronidazole reduction, in anaerobic condition, results in the formation of an 
intermediate body that binds to the DNA and proteins of the protozoan. This phenomenon 
inhibits the nucleic acid synthesis. 
Niclosamide is almost entirely absorbed from the oral route. Metronidazole has a well-
known mutagenic action against various animal species but disputed in humans based on 
extensive reassuring data available in pregnant women exposed to metronidazole. 
Metronidazole can therefore be used in pregnant women irrespective of the pregnancy 
term, although with caution during the first trimester. It is indicated in the treatment of 
amoebiasis at the dosage of 20-30 mg/kg per day divided into three daily intakes with food, 
for 7 to 10 days. Shorter treatment durations are possible to treat giardiasis or 
trichomoniasis. Alternatives with second-generation products, prescribed at the oral dose of 
2 grams as a one-dose treatment, such as tinidazole (Fasigyne®) or secnidazole (Secnol®), or 
injectable drugs such as ornidazole (Tiberal®) may be considered after the first trimester. 
Although no teratogenic effect has been reported in animal models, data is currently scarce 
to recommend this treatment in a first-line setting. 
 
b. Benzimidazoles 
Albendazole may be prescribed to treat giardiasis patients who do not respond to a 5-
nitroimidazole-based treatment (65).  
 
c. Aminoglycosides 
Paromomycin (Humagel®) is a topical aminoglycoside with partial efficacy against 
cryptosporidiosis. It only has a temporary marketing authorization and is contraindicated in 
pregnant women. 
 
d. Inhibitors of folic acid synthesis 
The combination of sulfamethoxazole-trimethoprim (Bactrim®), at the dosage of 800 mg - 
160 mg four times a day for 10 days, is effective against some coccidia such as Cyclospora 
cayetanensis and Cystoisospora belli.  
 
e. Nitrothiazoles 
Nitazoxanide (Alinia®) has a temporary marketing authorization and has been proved 
effective in controlling the parasitic load during intestinal cryptosporidiosis at the daily dose 
of 1 to 2 gram(s) (65). This drug must be used with caution in pregnant women because of 
the lack of hindsight and studies performed in this population (66). 
 
CONCLUSION 
The management of parasitic infections in pregnant women is difficult because of data 
scarcity and lack of power of current guidelines. The analysis of literature data published 
over the past decades highlights the numerous remaining uncertainties. Numerous pieces of 
data cannot be used because of the poor methods used in the initial clinical studies and 
because of the small number of pregnant women included in the studies. The example of 
mefloquine, which safety in pregnant women was discovered inadvertently, highlights that 
the choice of antiparasitic drugs is rather based on acquired experience than robust 
experimental data. The benefit-risk ratio associated with the prescription of an antiparasitic 
drug in case of a fatal infection is evaluated based on the severity and on the life-threatening 
risk incurred by the mother, and sometimes despite the associated consequences for the 
unborn child.  
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Tableau I. Liste des principaux médicaments antiparasitaires possiblement utilisables chez la femme enceinte  
Table I. Listing of the main antiparasitic drugs that can be used in pregnant women 
International Nonproprietary Name 
(Drug) 
Administration 
route 
Potential administration in pregnant women 
1st trimester  2nd trimester  3rd trimester 
Chloroquine 
(NIVAQUINE®) 
Oral and 
parenteral 
   
Chloroquine/proguanil  
(SAVARINE®) 
Oral    
Primaquine Oral    
Quinine 
(QUINIMAX®, SURQUINA®, QUININE LAFRAN®) 
Oral and 
parenteral 
   
Mefloquine 
(LARIAM®) 
Oral May be considered   
Lumefantrine/artemether  
(RIAMET®) 
Oral May be considered   
Pyrimethamine/sulfadoxine  
(FANSIDAR®) 
Oral    
Doxycycline 
(Vibramycine®) 
Oral  May be considered May be considered 
Artesunate  
(MALACEF®) 
Parenteral    
Atovaquone/proguanil  
(MALARONE®) 
Oral May be considered May be considered May be considered 
Spiramycin 
(ROVAMYCINE®) 
Oral and 
parenteral 
   
Pyrimethamine  
(MALOCIDE®) 
Oral    
Sulfadiazine  
(ADIAZINE®) 
Oral    
Sulfamethoxazole/trimethoprim  Oral and May be considered#   
(BACTRIM®) parenteral 
Meglumine antimoniate  
(GLUCANTINE®) 
Intramuscular    
Sodium stibogluconate  
(PENSTOTAM®) 
Parenteral    
Pentamidine 
(PENTACARINAT®) 
Parenteral and 
intramuscular 
 May be considered May be considered 
Amphotericin B deoxycholate 
(FUNGIZONE®) 
Parenteral    
Liposomal amphotericin B 
(AMBISOME®) 
Parenteral    
Suramin 
(MORANYL®) 
Parenteral    
Eflornithine 
(ORNIDYL®) 
Parenteral May be considered May be considered May be considered 
Melarsoprol 
(ARSOBAL®) 
Parenteral    
Benznidazole  
(RADANIL®) 
Oral  May be considered May be considered 
Nifurtimox 
(LAMPIT®) 
Oral  May be considered May be considered 
Albendazole  
(ZENTEL®) 
Oral May be considered   
Flubendazole 
(FLUVERMAL®) 
Oral May be considered   
Mebendazole  
(VERMOX®) 
Oral May be considered   
Triclabendazole 
(Egaten®) 
Oral May be considered May be considered May be considered 
Pyrantel Oral    
(COMBANTRIN®) 
Ivermectin 
(STROMECTOL®) 
Oral * * * 
Praziquantel  
(BILTRICIDE®) 
Oral    
Niclosamide  
(TREDEMINE®) 
Oral    
Metronidazole 
(FLAGYL®) 
Oral and 
parenteral  
May be considered   
Tinidazole (FASIGYNE®), secnidazole (SECNOL®), 
ornidazole (TIBERAL®) 
Oral and 
parenteral 
May be considered May be considered May be considered 
Abréviation : # supplémentation en acide folique à la dose journalière de 5 mg par jour, et surveillance échographique ciblée ;  uniquement 
envisageable en cas de risque vital ;  surveillance du volume de liquide amniotique ; un bilan de la fonction rénale du nouveau-né pourra être 
envisagé à la naissance, en particulier dans les cas exceptionnels de traitements prolongés ; * uniquement envisageable en cas d’usage 
prophylactique. 
 Abbreviation: # folic acid supplementation at the daily 5-mg dosage, and targeted ultrasound monitoring;  only possible in the event of a life-
threatening condition;  monitoring of amniotic fluid volume; a control of the newborn’s renal function may be considered at birth, especially 
in exceptional cases of prolonged treatment; * only possible in case of a prophylactic use. 
 
 
